Treatment and outcome in nasal and extranasal NK/T-cell lymphoma
| Clinical features . | Nasal, % . | Extranasal, % . | P . |
|---|---|---|---|
| Patients treated | 98 | 81 | .0009 |
| Anthracycline used | 89 | 76 | .08 |
| Radiotherapy alone vs radiotherapy and chemotherapy vs chemotherapy alone | 9 vs 43 vs 48 | 12 vs 12 vs 76 | .018 |
| CR/CRu achieved | 50 | 26 | .04 |
| Disease relapse | 56 | 67 | .37 |
| HSCT performed | 9.6 | 7.1 | .70 |
| Patients dead | 55 | 88 | .0007 |
| Clinical features . | Nasal, % . | Extranasal, % . | P . |
|---|---|---|---|
| Patients treated | 98 | 81 | .0009 |
| Anthracycline used | 89 | 76 | .08 |
| Radiotherapy alone vs radiotherapy and chemotherapy vs chemotherapy alone | 9 vs 43 vs 48 | 12 vs 12 vs 76 | .018 |
| CR/CRu achieved | 50 | 26 | .04 |
| Disease relapse | 56 | 67 | .37 |
| HSCT performed | 9.6 | 7.1 | .70 |
| Patients dead | 55 | 88 | .0007 |
CR indicates complete remission; CRu, unconfirmed complete remission; and HSCT, hematopoietic stem cell transplantation (both autologous and allogeneic).